ArticleFrontiers in immunology2026
Functional profiling of porcine precision-cut lymph node slices as an
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Precision-cut lymph node slices (PCLNS) provide a physiologically relevant ex vivo model to investigate lymphoid immune activation and vaccine adjuvant function while preserving native tissue architecture. In this study, we established for the first time porcine PCLNS and assessed the immunostimulatory capacity of PCLNS to Toll-like receptor (TLR) 7/8 agonist (Resiquimod; R848) alone or in combination with porcine circovirus type 2 (PCV2) or PCV2 virus-like particles (VLPs). Methods: Lymph nodes (LNs) were collected from PCV2-vaccinated pigs. PCLNS were generated using a Krumdieck tissue slicer and cultured in vitro with R848, PCV2, VLPs and their combinations Supernatants were collected daily for cytokine quantification and PCV2-specific antibody detection. Flow cytometry and immunofluorescence imaging were performed to examine B cell responses. Results: PCLNS maintained viability and preserved key histological structures over a five-day culture period, although progressive follicular depletion developed across conditions, potentially due to yet suboptimal culture condition. Phenotypic profiling revealed that R848 induces stronger B cell activation, including increased Ki-67 expression and plasma cell expansion. These cellular responses were accompanied by rapid and selective induction of IL-10, IL-12 and TNF following R848 stimulation. Daily supplementation with B cell survival factors (CD40L, BAFF and IL-21) failed to prevent germinal centre (GC) collapse despite modest effects on viability. Stimulation of PCLNS with PCV2 elicited detectable PCV2-specific IgG but not IgM, with the strongest humoral and cytokine responses observed following combined PCV2 and R848 stimulation, indicating a potential synergistic enhancement of recall-like immune response. In contrast, VLPs induced minimal antibody responses even with R848 co-stimulation. Collectively, these findings establish PCLNS as a tractable platform for assessing adjuvant-driven immune activation and demonstrate that TLR7/8 engagement seems to be a superior driver of B cell proliferation, plasma cell differentiation and pro-inflammatory cytokine production compared to other B cell survival factors, in porcine lymphoid tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.